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Treatment of trichomoniasis in pregnancy in sub-Saharan 
Africa does not appear to be associated with low birth 
weight or preterm birth
Elizabeth Stringer, Jennifer S Read, Irving Hoffman, Megan Valentine, Said Aboud, Robert L Goldenberg 
Preterm birth is an important cause of neonatal morbidity and 
mortality worldwide.1,2 Studies have suggested that bacterial 
infections of the placenta and fetal membranes may play a 
major role in preterm birth.3,4 Although the most common 
micro-organisms associated with preterm birth are Ureaplasma 
urealyticum, Mycoplasma hominis, Gardnerella vaginalis, 
Bacteroides species, Mobiluncus curtsii and a variety of anaerobic 
species, some studies have suggested that infection with 
Trichomonas vaginalis may increase the risk of preterm birth.5 A 
high prevalence of trichomoniasis among adults in eastern and 
southern Africa, ranging from 17% to 42%, has been reported.6-8 
Use of antibiotics to prevent preterm labour and premature 
membrane rupture, or to reduce the risk of preterm birth for 
women in preterm labour, has been widely studied for over 30 
years. About a third of the studies have suggested benefit in 
reducing preterm birth, while most have not.9-11
Two studies have suggested that treatment of trichomoniasis 
with metronidazole in pregnancy is associated with an 
increased risk of preterm birth and low birth weight.12,13 In 
one of these, a multicentre trial in the USA, women with 
asymptomatic trichomoniasis treated with metronidazole 
were significantly more likely than those not treated to deliver 
a preterm infant.12 The second, a sub-analysis of a study in 
rural Uganda, showed that women who were treated for 
trichomoniasis were 2.5 times more likely to deliver a low-
birth-weight infant compared with controls.13
In a planned secondary analysis we hypothesised, on the 
basis of these earlier studies, that women with trichomoniasis 
who were randomised to the study group given metronidazole 
(active against T. vaginalis) would have a higher rate of preterm 
and low-birth-weight infants than women randomised to 
placebo.
Materials and methods
HPTN 024 was a trial of antibiotics to reduce both mother-to-
child transmission of HIV and preterm birth.14 The first women 
were enrolled in July 2001, and the last delivery occurred in 
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Objectives. To determine whether treatment of trichomoniasis 
increases the risk of prematurity.
Design. Sub-analysis of a randomised trial.
Setting. We analysed data from HPTN 024, a randomised 
trial of antenatal and intrapartum antibiotics to reduce 
chorioamnionitis-related perinatal HIV transmission.
Subjects. Pregnant women from four sites in Africa.
Outcome measures. Gestational age at the time of delivery or 
mean birth weight.
Results. Of 2 428 women-infant pairs included, 428 (18%) had 
trichomoniasis at enrolment. There were no differences in 
infant age or birth weight between women with or without 
trichomoniasis. By randomisation group, there were no 
differences in gestational age at birth or birth weight. Of 
the 428 women diagnosed with trichomoniasis, 365 (83%) 
received antibiotics and 63 (15%) did not. In analysis of actual 
use of antibiotics, women with trichomoniasis who received 
no treatment were more likely to deliver a preterm infant 
when the symphysis-fundal height was used to estimate 
gestational age (36% v. 23%; p=0.03), but not when the 
Ballard score was used (16% v. 21%; p=0.41). There were no 
differences in mean birth weight between groups.
Conclusions. In pregnant women in sub-Saharan Africa, most 
of whom were HIV-infected, neither trichomoniasis nor its 
treatment appears to influence the risk of preterm birth or a 
low-birth-weight infant.
S Afr Med J 2010; 100: 58-64.
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August 2003. The study was conducted in four sub-Saharan 
African sites: Blantyre and Lilongwe, Malawi; Dar es Salaam, 
Tanzania; and Lusaka, Zambia. Enrolment required knowledge 
of HIV infection status. In three of the four sites, 1 HIV-
uninfected woman was enrolled for every 5 infected women 
in order to mask HIV infection status. In Dar es Salaam, only 
HIV-infected women were enrolled. Women were enrolled 
between 20 and 24 weeks.
At enrolment, blood for syphilis testing and cervico-vaginal 
samples were obtained. Vaginal samples were analysed by 
microscopy in site laboratories for the presence of motile 
Trichomonas, candidiasis and bacterial vaginosis (through 
whiff test, vaginal pH, and presence of clue cells). Cotton-
tipped applicators were also used to collect vaginal specimens 
for Gram staining, which were shipped to the University of 
Alabama at Birmingham for evaluation. For gonococcal culture, 
a cotton-tipped swab was placed in the endocervical canal and 
allowed to sit for at least 10 seconds. This swab was then used 
to inoculate a plate for gonococcal isolation. Chlamydia infection 
was detected by Chlamydia trachomatis antigen enzyme 
immunosorbent assay. Women were offered treatment for these 
infections at no cost, although treatment regimens differed 
across the sites. 
Women were randomised to receive either antibiotics 
(metronidazole 250 mg and erythromycin 250 mg orally, both 3 
times daily for 7 days) or placebo. Tests were repeated between 
26 and 30 weeks’ gestation for bacterial vaginosis, vaginal 
candidiasis and trichomoniasis. Women found to have any 
of these infections were treated, but not all women received 
treatment.  With the onset of labour contractions and/or 
premature rupture of membranes (PROM), study participants 
initiated a second oral course of antibiotics consisting of 
metronidazole 250 mg orally and oral ampicillin 500 mg or 
placebo every 4 hours until delivery. These antibiotics were 
chosen because the organisms associated with clinical or 
sub-clinical chorioamnionitis (bacterial vaginosis-associated 
organisms such as Ureaplasma, Mycoplasma, Bacteroides, 
Mobiluncus and Gardnerella) are generally sensitive to one or 
more of these antibiotics.15
Because the study was conducted in four resource-limited 
settings and ultrasound was not generally available, it was 
not used to determine the estimated due date. Gestational age 
was determined by patient recall of the last menstrual period 
(LMP), corroborated with uterine size. If uterine size was 
not within 2 weeks of recall of the LMP, uterine size defined 
the obstetric gestational age. At delivery, each baby also had 
a modified Ballard examination to allow for a paediatric 
estimation of gestational age.16  If the Ballard examination 
and obstetric gestational age determination were consistent 
within 2 weeks, the obstetric gestational age was used; if 
not, the final study gestational age was based on the Ballard 
examination. Nurses at all locations were trained to determine 
both the obstetric and the paediatric gestational ages. Preterm 
birth was defined as birth occurring before 37 completed weeks 
of gestation, low birth weight as birth weight less than 2 500 g,  
and very low birth weight as birth weight less than 1 500 g. 
Results are presented independently for each of the methods. 
The analysis was restricted to singleton deliveries because 
twins have a higher baseline risk of preterm birth.17
Statistical analysis 
We performed a secondary analysis using data from the HPTN 
024 trial.11 Independent two-sample t-tests, Wilcoxon rank 
sum tests and two-sample chi-square tests were performed 
to compare means, medians, and proportions, respectively. 
Kaplan-Meier estimates were calculated and log rank tests 
were performed in time-to-event analysis of time to delivery 
following randomisation.
Results
A total of 2 661 women were enrolled into HPTN 024 trial and 
randomised (86% of whom were HIV infected). Of these, 2 656 
(almost 100%) had a baseline trichomoniasis result, but 188 
(7%) were lost to follow-up before delivery, 32 (1%) delivered 
twins, 7 died before delivery, and 1 woman’s delivery outcome 
was unknown. The study population therefore comprised 2 428 
mother-infant pairs. Characteristics of the study population 
according to presence or absence of trichomoniasis at 
enrolment are set out in Table I. Compared with those without 
trichomoniasis, women with trichomoniasis were more likely 
to be HIV infected, to have bacterial vaginosis or gonorrhoea, 
to be younger, and to be slightly less educated (Table I).
Of the 428 women diagnosed with trichomoniasis, 231 (54%) 
were randomised to receive the study antibiotics and 197 (46%) 
were randomised to placebo (Table II and Fig. 1). There were 
no significant differences in baseline characteristics between 
the two groups. Women randomised to receive antibiotics 
were more likely to have resolution of trichomoniasis at their 
second visit than women randomised to placebo (p<0.0001). 
In the analysis by randomisation group, women randomised 
to the antibiotic arm were not more likely to deliver a preterm 
infant, whether the gestational age was based on fundal 
height obtained at randomisation (23.8% v. 27.4%; p=0.39) or 
on Ballard examination (20.6% v. 19.8%; p=0.84) or to deliver 
an infant with a lower mean birth weight (2 992 g v. 2 930 g; 
p=0.27) (Table II).   
A second analysis was performed based on actual 
metronidazole use. Of the 428 women diagnosed with 
trichomoniasis, 365 (85%) received antibiotics active against 
trichomoniasis and 63 (17%) did not (Fig. 1). Women who 
received antibiotics active against trichomoniasis were more 
likely to have a Chlamydia infection and to have resolution of 
the trichomoniasis at their second visit compared with women 
who did not (p<0.001). Women who were diagnosed with 
trichomoniasis but did not receive antibiotics active against 
this infection were more likely to deliver a preterm infant 
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when that assessment was based on symphysis-fundal height 
gestational age assessment (40% v. 23%; p=0.005), but not when 
the gestational age assessment was based on Ballard estimation 
(19% v. 20%; p=0.97). There were no differences in mean birth 
weights at delivery between women not receiving and those 
receiving treatment for trichomoniasis (2 972 g and 2 911 g, 
respectively) (Table III).  
To examine the association of receipt of antibiotics and infant 
outcomes further among women with treated trichomoniasis, 
we examined time from randomisation to delivery for women 
with trichomoniasis who were treated with antibiotics 
compared with those who were not treated, since calculation 
of gestational age may be inaccurate without an ultrasound 
scan. There was no difference in the time from randomisation 
to delivery between those with treated and untreated 
trichomoniasis (log-rank p-value = 0.12) (data not shown).
Discussion
We found no differences in pregnancy outcomes among 
women diagnosed with trichomoniasis compared with women 
without trichomoniasis. Analysis of the treatment results of 
women who had trichomoniasis by both randomisation arm 
and actual-use analysis found no substantial differences in 
pregnancy outcomes. Women in the actual-use analysis who 
received metronidazole were more likely to have a preterm 
infant when gestational age was based on fundal height 
obtained at randomisation, but not when it was based on 
modified Ballard examination. In addition, there were no 
significant differences in infant birth weights between women 
with trichomoniasis according to randomisation arm or actual 
receipt of antibiotics. The time to delivery also did not differ 
according to randomisation arm or actual receipt of antibiotics. 
Table I. Characteristics of women and their infants, according to presence or absence of trichomoniasis (N=2 428) 
           With trichomoniasis              Without trichomoniasis
Characteristic          (N 428)               (N 2 000)    p-value 
Categorical variables* (N (%))
Maternal
    History of stillbirth          33/428 (7.7)               162/2 000 (8.1)   0.79
    Married           387/428 (90.4)               1 856/2 000 (92.8)   0.09
    HIV infected          392/428 (91.6)               1 701/2 000 (85.0)   0.004
STI 
    Bacterial vaginosis         217/428 (50.7)               867/2 000 (43.3)   0.003
    Chlamydia          10/428 (2.3)               47/2 000 (2.3)   0.94
    Syphilis          36/428 (8.4)               120/2 000 (6.0)   0.07
    Gonorrhoea           14/428 (3.3)               24/2 000 (1.2)   0.002
Delivery
    Duration of rupture of         75/389 (19.3)               360/1 852 (19.4)   0.94
    membranes >4 h
    Vaginal delivery          405/427 (94.8)               1 878/1 998 (94.0)   0.50
Infant
    Preterm birth 
       By fundal height         109/428 (25.5)               497/2 000 (24.9)   0.80
       By Ballard examination         71/351 (20.2)               349/1 729 (20.2)   0.99
   Birth weight (g)
      <1 500          10/389 (2.6)               42/1 859 (2.3)   0.98
       1 501 - 2 500           63/389 (16.2)               296/1 859 (15.9)
       2 501 - 3 000           140/389 (36.0)               669/1 859 (36.0)
       ≥3 001           176/389 (45.2)               852/1 859 (45.8)
Continuous variables†
(median  (IQR))
Age (yrs)           24.0 (21 - 27)               25.0 (21 - 28)    0.002
No. of pregnancies          3.0 (2 - 4)               3.0 (2 - 4)    0.42
No. of live births          1.0 (1 - 3)               1.0 (1 - 3)    0.79
Years of education           7.0 (3 - 8)               7.0 (5 - 9)    0.0002
Baseline CD4 count (cells/µl)         386 (238 - 566)               366 (226 - 564)   0.43
Baseline fundal height (cm)          22.0 (20 - 24)               22.0 (20 - 24)    0.70
Birth weight (g)          3 000 (2 700 - 3 300)              3 000 (2 700 - 3 300)   0.95
*p-values based on the χ2 test.
†p-values based on the Wilcoxon rank sum test.
STI = sexually transmitted infection; IQR = intraquartile range.
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A systematic review of well-conducted studies of pregnant 
women with either bacterial vaginosis or trichomoniasis 
receiving antibiotics in the second or third trimesters 
concluded that treatment of trichomoniasis in pregnancy 
may be harmful.18 This conclusion was primarily based on 
two studies. One showed that women with asymptomatic 
trichomoniasis treated with two 2 g doses of metronidazole 
48 hours apart were more likely to have a preterm infant 
(relative risk (RR) 1.8, 95% confidence interval (CI) 1.2 - 2.7), 
but were not more likely to have a low-birth-weight infant (RR 
1.4, 95% CI 0.9 - 2.1).12 The second study was a sub-analysis 
from a large community randomised trial in Uganda.13 This 
study found that pregnant women with trichomoniasis in the 
treatment arm (which included 2 g metronidazole) were 2.5 
times as likely to deliver a low-birth-weight infant at 1 week 
of follow-up compared with women in the untreated arm. A 
major limitation of this study was its preferential follow-up of 
infants in the treatment arm; 84% of infants born to women in 
the treatment group were followed up within the first week, 
as opposed to only 67% of infants in the control group. In 
addition, there was no statistically significant difference in 
gestational age at birth between the control and treatment 
arms. Another observational study conducted in South Africa 
found no difference in mean birth weight or gestational 
age between infants born to women who were treated for 
trichomoniasis and those who were not.19
Our results are consistent with the findings in other 
studies that women who received antibiotic treatment for 
trichomoniasis are more likely to have resolution of their 
trichomoniasis. For example, trichomoniasis in our study was 
reduced by 68% in the group who received antibiotics active 
against trichomoniasis versus 21% in the placebo group (as 
previously reported).  Women diagnosed with trichomoniasis 
in our population also were more likely to have other 
infections such as HIV infection, bacterial vaginosis, Chlamydia 
infection, and gonorrhoea than women without trichomoniasis. 
One limitation of our study is that a significant number of 
women randomised to the placebo arm in HPTN 024 were 
exposed to metronidazole. Because of this we also performed 
an actual-use analysis, for which results were similar to those 
of the intention-to-treat analysis. Another limitation of this 
study is in the imperfect gestational age dating using fundal 
height estimation and the modified Ballard examination. Since 
the modified Ballard examination can be performed only on 
women who deliver at a health centre, all of the women who 
were lost to follow-up, had a stillbirth, or delivered at home 
could not have a Ballard examination performed on their 
infant. The sample size for analyses including a modified 
Ballard examination was therefore diminished.   
In conclusion, data regarding whether treatment of 
trichomoniasis in pregnancy is associated with adverse infant 
outcomes is limited by variation in the types of study, study 
size and even treatment regimens. In addition, some studies 
have examined treatment of asymptomatic trichomoniasis 
while others, such as ours, have examined antibiotic receipt by 
both asymptomatic and symptomatic subjects. Our results for 
sub-Saharan African women, mostly HIV-infected and with a 
high prevalence of trichomoniasis, do not indicate an increased 
risk of preterm birth according to both intention-to-treat and 
actual-use analyses. While this study was not designed to 
provide conclusive evidence of safety, we believe that our 
results, taken with other available evidence, do not suggest that 
treatment of trichomoniasis is associated with a substantially 
increased risk of preterm birth among HIV-infected African 
women.
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Fig. 1. Profile of women with trichomoniasis at baseline.
January 2010, Vol. 100, No. 1  SAMJ
ORIGINAL ARTICLES
62
and opinions expressed in this paper are those of the authors 
and do not necessarily reflect those of the funding agencies and 
participating institutions.
HPTN 024 Team: Protocol Co-Chairs: Taha E Taha, MD, PhD 
(Johns Hopkins University Bloomberg School of Public Health); 
Robert Goldenberg, MD (University of Alabama at Birmingham); 
In-Country Co-Chairs/Investigators of Record: Newton Kumwenda, 
PhD, George Kafulafula, MB BS, FCOG (Blantyre, Malawi); Francis 
Martinson, MD, PhD (Lilongwe, Malawi); Gernard Msamanga, 
MD, ScD (Dar es Salaam, Tanzania); Moses Sinkala, MD, MPH, 
Jeffrey Stringer, MD (Lusaka, Zambia); US Co-Chairs: Irving 
Hoffman, PA, MPH (University of North Carolina, Chapel Hill);  
Wafaie Fawzi, MD, DrPH (Harvard School of Public Health ); 
In-Country Investigators, Consultants and Key Site Personnel: Robin 
Broadhead, MB BS, FRCP, George Liomba, MB BS, FRCPath, 
Johnstone Kumwenda, MB ChB, MRCP, Tsedal Mebrahtu, ScM,  
Pauline Katunda, MHS, Maysoon Dahab, MHS (Blantyre, Malawi); 
Peter Kazembe, MB ChB, David Chilongozi, CO, MPH, Charles 
Chasela, CO, MPH, George Joaki, MD, Willard Dzinyemba, Sam 
Kamanga (Lilongwe, Malawi); Eligius Lyamuya, MD, PhD, Charles 
Kilewo, MD, MMed, Karim Manji, MD, MMed, Sylvia Kaaya, 
MD, MS, Said Aboud, MD, MMed, Muhsin Sheriff, MD, MPH, 
Elmar Saathoff, PhD, Priya Satow, MPH, Illuminata Ballonzi, 
SRN, Gretchen Antelman, ScD, Edgar Basheka, BPharm (Dar 
es Salaam, Tanzania); Victor Mudenda, MD, Christine Kaseba, 
MD, Maureen Njobvu, MD, Makungu Kabaso, MD, Muzala 
Kapina, MD,  Anthony Yeta, MD, Seraphine Kaminsa, MD, MPH, 
Constantine Malama, MD, Dara Potter, MBA, Maclean Ukwimi, 
RN, Alison Taylor, BSc, Patrick Chipaila, MSc, Bernice Mwale, 
BPharm (Lusaka, Zambia); US Investigators, Consultants and Key Site 
Personnel: Priya Joshi, BS, Ada Cachafeiro, BS, Shermalyn Greene, 
PhD, Marker Turner, BS,  Melissa Kerkau, BS, Paul Alabanza, BS, 
Table II. Characteristics of women with trichomoniasis, according to randomisation arm (N=428)
      Antibiotics  Placebo 
Characteristic     (N=231)   (N=197)   p-value
Categorical variables* (N (%))
Maternal    
      Reported history of stillbirth    17/231 (7.4)  16/197 (8.1)  0.77
      Married      208/231 (90.0)  179/197 (90.9)  0.77
History of STI
      HIV infected      217/231 (93.9)  175/197 (88.8)  0.06
      Bacterial vaginosis    116/227 (51.1)  101/191 (52.9)  0.60
      Chlamydia      3/217 (1.4)  7/195 (3.6)  0.15
      Syphilis      18/228 (7.9)  18/196 (9.2)  0.07
      Gonorrhoea      7/223 (3.1)  7/195 (3.6)  0.80
Delivery
      >4 hours between rupture of membranes and 
        delivery          42/206 (20.4)  33/183 (18.0)  0.56
      Vaginal delivery     219/230 (95.3)  186/197 (94.4)  0.71
Infant 
      Gestational age at time of delivery (wks)
         <37 (fundal height)    55/231 (23.8)  54/197 (27.4)  0.39
         <37 (Ballard score)    39/189 (20.6)  32/162 (19.8)  0.84
      Birth weight (g)
         <1 500      5/207 (2.4)  5/182 (2.7)  0.92
          1 501 - 2 500      32/207 (15.5)  32/182 (17)
          2 501 - 3 000     73/207 (35.3)  67/182 (36.8)
         ≥3 001     97/207 (46.9)  76/182 (43.4)
Other
       Resolution of trichomoniasis by visit 2   192/224 (85.7)  126/186 (67.7)  <0.0001
Continuous variables† (median (IQR))
Age      24.0 (21 - 27)  23.0 (21 - 27)  0.35
No. of pregnancies     3.0 (2 - 4)   3.0 (2 - 4)   0.15
No. of live births     2.0 (1 - 3)   1.0 (0 - 2)   0.19
Years of education     7.0 (3 - 9)   7.0 (3 - 8)   0.36
Baseline CD4 count (cells/µl)    378 (238 - 518)  398 (238 - 638)  0.14
Baseline fundal height (cm)    22.0 (20 - 24)  22.0 (20 - 24)  0.77
Birth weight (g)     3 000 (2 700 - 3 300)  3 000 (2 700 - 3 300)  0.41
*p-values based on the χ2 test.
†p-values based on the Wilcoxon rank sum test.
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Categorical variables* (N (%))
Maternal    
   Reported history of stillbirth   30/365 (8.2)   3/63 (4.8)    0.34
   Married     333/365 (91.2)   54/63 (85.7)   0.17
STI
   HIV infected    335/365 (91.8)   54/ 63 (85.7)   0.07
   Bacterial vaginosis   191/365 (52.3)   26/63 (41.3)   0.09
   Chlamydia    6/365 (1.6)   4/63 (6.3)    0.03
   Syphilis     29/365 (7.9)   7/63 (11.1)   0.39
   Gonorrhoea    12/365 (3.3)   2/63 (3.2)    0.93
Delivery
   Vaginal delivery     344/361 (95.3)   61/66 (96.8)   0.44
Infant 
   Gestational age at time of delivery (wks)
       <37 (fundal height)   84/365 (23.0)   25/63 (39.7)   0.005
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Other
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Age (yrs)     24.0 (21 - 27)   23.0 (20 - 26)   0.14
No. of pregnancies    3.0 (2 - 4)    2.0 (2 - 4)    0.33
No. of live births    2.0 (1 - 3)    1.0 (0 - 2)    0.22
Years of education    7.0 (3 - 8)    7.0 (5 - 8)    0.24
Baseline CD4 counts (cells/µl)  379 (237 - 534)   457 (266 - 666)   0.11
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Birth weight (g)    3 000 (2 650 - 3 300)   3 000 (2 720 - 3 300)   0.74
*p-values based on the χ2 test.
†p-values based on the Wilcoxon rank sum test.
STI = sexually transmitted infection; IQR = intraquartile range.
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